HOME >> MEDICINE >> NEWS
Int'l Assoc for Dental Research holds 83rd General Session

Honolulu, Hawaii...Did you know that how we eat, as much as what we eat, may have an effect on our oral and general health and well-being?that researchers are making the case for a vaccine against dental caries?...and that our genetic profile (not clinical appearance) may help determine how a tumor is treated?

These are but a few of the thousands of pieces of information which will be presented when the International Association for Dental Research (IADR) holds its 82nd General Session & Exhibition, March 10-13, 2004, at the Hawaii Convention Center in Honolulu, Hawaii. It will also be the 33rd Annual Meeting of the American Association for Dental Research and the 28th Annual Meeting of the Canadian Association for Dental Research.

This year, over 4,100 scientific presentations will be made, divided among plenary/oral/poster/poster discussion sessions and symposia/workshops. (For releases on selected topics, please see the white section of this Press Kit.) Estimates are that nearly 6,000 dental scientists, educators, students, and practicing dentists from around the world will convene, representing the latest thinking in dental research.

In addition to the individual presentations, there will be plenary sessions, symposia, and workshops during the four-day meeting, dealing with special-interest topics ranging from aspiration pneumonia to "dentists on Mars" to a dental caries vaccine. (For a complete listing, please see the green section of this Press Kit.)

Featured during Meeting Week will be both the IADR/Unilever Hatton Awards Competitions (40 competitors from 19 countries) and the AADR/Pfizer Hatton Awards Competition (27 competitors) for student investigators. The presentations, in poster format, will be judged by top-level scientists. Winners will receive cash prizes and plaques.

The Opening Ceremonies and Welcome Reception, from 4:15 to 7:00 p.m. on Wednesday, March 10, will provide an exciting kick-off for the week's activities.
'"/>

Contact: Linda Hemphill
linda@iadr.org
International & American Association for Dental Research
26-Feb-2004


Page: 1 2 3 4

Related medicine news :

1. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
2. Intl surveillance system suggests 2002 gastroenteritis outbreaks from new variant norovirus
3. Awards & fellowships at the International & American Association for Dental Research General Session
4. Canadian neurologist wins highest award as American Stroke Association honors five
5. Association publishes blueprint to strengthen stroke care from prevention through recovery
6. Association of herpesvirus with lung disorder questioned
7. Highlights of the December Journal of the American Dietetic Association
8. Highlights of the September Journal of the American Dietetic Association
9. Highlights of June Journal of the American Dietetic Association
10. New darifenacin data released at the American Urological Association (AUA)
11. News tips from the American Heart Association

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Int Assoc for Dental Research holds General Session

(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay ... (IVF) -- the incubation of embryos in a laboratory dish ... vagina, new research suggests. Scientists from the United States ... sharply cut costs for pricey IVF procedures among certain women. ... who don,t live near big-city assisted reproduction centers, the researchers ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
Cached News: